Anti-depressants and suicide

Area of Science:

• Psychiatry
• Pharmacoeconomics
• Public Health

Background:

• Suicide remains a significant global health issue, with depression as a major risk factor.
• Controversy exists regarding the impact of selective serotonin reuptake inhibitors (SSRIs) on completed suicide risk.
• Limitations of randomized clinical trials necessitate alternative research methods for assessing SSRI effects on suicide mortality.

Purpose of the Study:

• To estimate the effect of selective serotonin reuptake inhibitor (SSRI) sales on suicide mortality.
• To provide scientifically credible estimates using international data on SSRI sales and suicide rates.

Main Methods:

• Utilized data from 26 countries over a period of up to 25 years.
• Employed variation in SSRI sales driven by institutional factors (regulation, pricing, distribution) and general new drug sales growth.
• Conducted an econometric analysis to determine the relationship between SSRI sales and suicide mortality.

Main Results:

• An increase in SSRI sales of 1 pill per capita, representing 12% of 2000 sales levels, was associated with a 5% reduction in suicide.
• The study identified a statistically significant inverse relationship between SSRI availability and suicide rates.

Conclusions:

• Increased availability and sales of SSRIs are associated with decreased suicide mortality.
• The findings suggest a beneficial public health impact of widespread SSRI use in reducing suicide rates.
• Further research may explore mechanisms and optimal strategies for SSRI implementation in suicide prevention efforts.